BACKGROUND/AIM: The appearance of anti-adalimumab antibodies (AAAs) is associated with low serum adalimumab (ADA) trough levels and a decrease of clinical response. The goal of this study was to assess the accuracy and clinical utility of new immunoassays for serum ADA and AAA levels. PATIENTS AND METHODS: Serum ADA trough levels and AAA levels were measured using new immunoassays in 40 patients with Crohn's disease (CD) receiving ADA maintenance therapy. RESULTS: Serum ADA trough levels were 12.3 ± 9.6 μg/ml (n = 40) in CD patients, and 14 of 40 patients (35 %) were positive for AAAs. A negative correlation was observed between serum AAA levels and ADA trough levels (y = -6.02x + 18.7, r = -0.54, P < 0.001, n = 40). The ROC (receiver-operator curve) analyses indicated that an ADA trough of 5.9 μg/ml was optimal to maintain negative CRP (C-reactive protein) levels (≤0.3 mg/dl). The ADA trough levels were significantly lower in patients positive for AAAs (5.5 ± 5.4 μg/ml, n = 14) than in patients negative for AAAs (16.0 ± 9.5 μg/ml, n = 26). The CRP and ESR levels were significantly higher in AAA-positive patients than in AAA-negative patients. Serum albumin levels were significantly lower in AAA-positive patients. The positive rate for AAAs in patients who lost a response to infliximab (50 %) was significantly higher than that of anti-TNF-α drug naïve patients (12.5 %). CONCLUSIONS: These new assays for serum AAA trough and AAA levels are useful for routine clinical use and may help guide selection of optimal management strategies for IBD patients with a loss of response to ADA.
BACKGROUND/AIM: The appearance of anti-adalimumab antibodies (AAAs) is associated with low serum adalimumab (ADA) trough levels and a decrease of clinical response. The goal of this study was to assess the accuracy and clinical utility of new immunoassays for serum ADA and AAA levels. PATIENTS AND METHODS: Serum ADA trough levels and AAA levels were measured using new immunoassays in 40 patients with Crohn's disease (CD) receiving ADA maintenance therapy. RESULTS: Serum ADA trough levels were 12.3 ± 9.6 μg/ml (n = 40) in CDpatients, and 14 of 40 patients (35 %) were positive for AAAs. A negative correlation was observed between serum AAA levels and ADA trough levels (y = -6.02x + 18.7, r = -0.54, P < 0.001, n = 40). The ROC (receiver-operator curve) analyses indicated that an ADA trough of 5.9 μg/ml was optimal to maintain negative CRP (C-reactive protein) levels (≤0.3 mg/dl). The ADA trough levels were significantly lower in patients positive for AAAs (5.5 ± 5.4 μg/ml, n = 14) than in patients negative for AAAs (16.0 ± 9.5 μg/ml, n = 26). The CRP and ESR levels were significantly higher in AAA-positive patients than in AAA-negative patients. Serum albumin levels were significantly lower in AAA-positive patients. The positive rate for AAAs in patients who lost a response to infliximab (50 %) was significantly higher than that of anti-TNF-α drug naïve patients (12.5 %). CONCLUSIONS: These new assays for serum AAA trough and AAA levels are useful for routine clinical use and may help guide selection of optimal management strategies for IBDpatients with a loss of response to ADA.
Authors: Severine Vermeire; Maja Noman; Gert Van Assche; Filip Baert; Geert D'Haens; Paul Rutgeerts Journal: Gut Date: 2007-01-17 Impact factor: 23.059
Authors: L S Kiss; T Szamosi; T Molnar; P Miheller; L Lakatos; A Vincze; K Palatka; Z Barta; B Gasztonyi; A Salamon; G Horvath; G T Tóth; K Farkas; J Banai; Z Tulassay; F Nagy; M Szenes; G Veres; B D Lovasz; Z Vegh; P A Golovics; M Szathmari; M Papp; P L Lakatos Journal: Aliment Pharmacol Ther Date: 2011-08-24 Impact factor: 8.171
Authors: Geertje M Bartelds; Charlotte L M Krieckaert; Michael T Nurmohamed; Pauline A van Schouwenburg; Willem F Lems; Jos W R Twisk; Ben A C Dijkmans; Lucien Aarden; Gerrit Jan Wolbink Journal: JAMA Date: 2011-04-13 Impact factor: 56.272
Authors: Jean-Frédéric Colombel; William J Sandborn; Paul Rutgeerts; Robert Enns; Stephen B Hanauer; Remo Panaccione; Stefan Schreiber; Dan Byczkowski; Ju Li; Jeffrey D Kent; Paul F Pollack Journal: Gastroenterology Date: 2006-11-29 Impact factor: 22.682
Authors: Geertje M Bartelds; Carla A Wijbrandts; Michael T Nurmohamed; Steven Stapel; Willem F Lems; Lucien Aarden; Ben A C Dijkmans; Paul Peter Tak; Gerrit Jan Wolbink Journal: Ann Rheum Dis Date: 2007-02-14 Impact factor: 19.103
Authors: Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts Journal: Lancet Date: 2002-05-04 Impact factor: 79.321
Authors: M Allez; S Vermeire; N Mozziconacci; P Michetti; D Laharie; E Louis; M-A Bigard; X Hébuterne; X Treton; A Kohn; P Marteau; A Cortot; C Nichita; G van Assche; P Rutgeerts; M Lémann; J-F Colombel Journal: Aliment Pharmacol Ther Date: 2010-01 Impact factor: 8.171
Authors: Konstantinos Papamichael; Adam S Cheifetz; Gil Y Melmed; Peter M Irving; Niels Vande Casteele; Patricia L Kozuch; Laura E Raffals; Leonard Baidoo; Brian Bressler; Shane M Devlin; Jennifer Jones; Gilaad G Kaplan; Miles P Sparrow; Fernando S Velayos; Thomas Ullman; Corey A Siegel Journal: Clin Gastroenterol Hepatol Date: 2019-03-27 Impact factor: 11.382
Authors: Niels Vande Casteele; Brian G Feagan; Ann Gils; Séverine Vermeire; Reena Khanna; William J Sandborn; Barrett G Levesque Journal: Curr Gastroenterol Rep Date: 2014-04